In an interview with Targeted Oncology, Muhammad Siddiqui, MD, explained the role that palliative medicine plays in a cancer treatment plan and how oncologists and palliative care physicians can work together in patients’ best interests.
Sabrina Serani
Sabrina Serani is the assistant managing editor for Targeted Oncology.
Articles by Sabrina Serani
In an interview with Targeted Oncology, Daniel Wolff, MD, discussed findings from the phase 2 AGAVE-201 trial evaluating axatilimab as a potential treatment option for patients with chronic graft-vs-host disease.
The median overall survival at 19 months of patients with glioblastoma continues to benefit from treatment with olaptesed pegol plus radiation and bevacizumab.
Though climate change threatens everyone’s health and safety, those with cancer are increasingly vulnerable.
The phase 3 RELATIVITY-123 trial in metastatic microsatellite stable colorectal cancer is not expected to meet its primary end point upon completion and is being discontinued due to futility.
Findings from 3-year follow-up of KEYNOTE-942/mRNA-4157-P201 show that the cancer vaccine mRNA-4157 plus pembrolizumab reduced the risk of recurrence or death in patients with stage III/IV melanoma following resection.
Anlotinib, a novel multi-targeting tyrosine kinase inhibitor, and icotinib, a first-generation EGFR TKI, demonstrated efficacy and tolerability in the first line for the treatment of patients with EGFR-mutated advanced non–small cell lung cancer.
Findings from the phase 3 PERSEUS study found the safety profile of D-VRd in newly diagnosed multiple myeloma to be in line with the known profiles of the agents.
Trastuzumab administered subcutaneously delivered unique immunomodulation effects vs intravenous trastuzumab in patients with treatment-naive HER2-positive breast cancer.
Antibody-based DLL3-targeting agents and antibody-drug conjugates present exciting treatment possibilities in small cell lung cancer, according to a presentation by Charles Rudin, MD, at the 18th Annual New York Lung Cancer Symposium.
The combination of vibostolimab and pembrolizumab plus docetaxel did not significantly improve progression-free survival compared with docetaxel monotherapy in patients with previously treated metastatic non–small cell lung cancer.
The phase 3 LEAP-001 trial did not meet its primary end points of overall survival and progression-free survival.
The phase 3 KEYLYNK-008 trial investigating pembrolizumab and olaparib in metastatic squamous non–small cell lung cancer will be stopped due to futility.
TAR-200, a novel targeted therapy, has been granted breakthrough therapy designation by the FDA in high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin.
The FDA has granted priority review to the supplemental biologics application of mirvetuximab soravtansin-gynx for the treatment of patients with platinum-resistant ovarian cancer.
Results from a retrospective study found that patients with certain features were at a greater risk of recurrence of papillary thyroid cancer.
Summary: The FDA has accepted for priority review nivolumab and cisplatin-based chemotherapy as a first line of treatment in patients with inoperable or metastatic urothelial carcinoma.
Recent findings identified that overall and cancer-specific mortality risks were lowered in patients who used antidepressants following a diagnosis with hepatocellular carcinoma compared with patients that did not.
The FDA has granted accelerated approval to pirtobrutinib for the treatment of patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
No serious adverse events or dose-limiting toxicities were observed in the phase 1/2 trial of the antibody drug conjugate ARX517.
Combining the glutaminase-1 inhibitor CB-839 and BCL-2 inhibitor venetoclax could be a new avenue for the treatment of diffuse large B-cell lymphoma.
The investigation follows reports of T-cell malignancies after treatment with chimeric antigen receptor T-cell immunotherapies.
A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.
A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Olvimulogene nanivacirepvec, an oncolytic viral-based therapy, has earned a fast track designation from the FDA in ovarian cancer resistant or refractory to platinum-based chemotherapy.
The phase 3 DREAMM-7 trial met its primary end point of progression-free survival, and overall survival data is trending positively.
The FDA breakthrough drug designation for epcoritamab in follicular lymphoma was supported by findings from the phase 1/2 EPCORE NHL-1 study.
Steady-state and chemotherapy-based mobilization both demonstrate feasibility in stem cell collection for patients with multiple myeloma undergoing autologous stem cell transplants, but challenges remain.
In an interview with Targeted Oncology, Jeff Stein, PhD, discussed the challenges and prospects of CD73-targeting agents.
In an interview with Targeted Oncology, Chris Haqq, MD, PhD, discussed the potential use of cancer vaccines in patients with KRAS-mutated pancreatic and colon cancer.